Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Persistent Idiopathic Facial Pain Medication

  • Author: Stanley J Krolczyk, DO, RPh; Chief Editor: Robert A Egan, MD  more...
 
Updated: Oct 24, 2014
 

Medication Summary

The goal of therapy is to manage the persistent facial pain with anticonvulsants and antidepressants. Narcotics may be appropriate if administered under careful supervision.

Next

Antidepressants, TCAs

Class Summary

Tricyclic antidepressants (TCAs) are a complex group of drugs that have central and peripheral anticholinergic effects and sedative effects. They block the active reuptake of norepinephrine and serotonin.

Amitriptyline

 

Amitriptyline increases the synaptic concentration of serotonin or norepinephrine in the central nervous system (CNS) by inhibiting their reuptake by the presynaptic neuronal membrane. It is useful as an analgesic for certain types of chronic and neuropathic pain.

Nortriptyline (Pamelor)

 

Nortriptyline has demonstrated effectiveness in the treatment of chronic pain. It increases the synaptic concentration of serotonin or norepinephrine in the CNS by inhibiting their reuptake by the presynaptic neuronal membrane. Additional pharmacodynamic effects, such as desensitization of adenyl cyclase and downregulation of beta-adrenergic receptors and serotonin receptors, appear to play roles.

Duloxetine (Cymbalta)

 

Duloxetine is approved by the US Food and Drug Administration (FDA) for diabetic peripheral neuropathic pain. It is a potent inhibitor of neuronal serotonin and norepinephrine reuptake.

Previous
Next

Anticonvulsants

Class Summary

Although anticonvulsants are useful for neuropathic pain, their mechanism of action in this setting is unknown.

Carbamazepine (Tegretol, Carbatrol, Epitol)

 

Carbamazepine has antineuralgic effects. It may depress the activity of the nucleus ventralis of the thalamus or may decrease synaptic transmission or summation of temporal stimulation, thus leading to neural discharge by limiting the influx of sodium ions across the cell membrane or through other unknown mechanisms. The target blood serum concentration range is 4-12 mg/L.

Pregabalin (Lyrica)

 

Pregabalin is FDA-approved for use in postherpetic neuralgia and painful diabetic peripheral neuropathy. Compared with placebo, it brings about a statistically significant reduction in mean pain score and pain-related sleep interference.

Pregabalin binds with high affinity to the alpha2-delta subunit of voltage-gaited calcium channels, thereby reducing excitatory neurotransmitters. It has a half-life of about 6 hours and is eliminated via renal excretion. A decrease in creatinine clearance results in decreased elimination and, therefore, a higher plasma concentration. Peak plasma concentration occurs at 1 and 1.5 hours after oral intake. Bioavailability is 90%. After repeated dosing, steady-state concentration is achieved at 24-48 hours. The drug can be taken with or without food.

Gabapentin (Neurontin, Gralise)

 

Gabapentin has properties common to other anticonvulsants and exerts antineuralgic effects. Its exact mechanism of action is not known. Gabapentin is structurally related to gamma-aminobutyric acid (GABA) but does not interact with GABA receptors. It has efficacy at the alpha2-delta subunit.

Phenytoin (Dilantin, Phenytek)

 

Phenytoin may stabilize neuronal membranes and treat neuralgia by increasing efflux or decreasing influx of sodium ions across cell membranes in the motor cortex during generation of nerve impulses. When the serum level is in or near the therapeutic range, adjust the dose in 30- to 50-mg increments. Small increments may cause greater than expected increases in serum concentration (ie, Michaelis-Menten drug kinetics). Because half-life is concentration-dependent, steady-state serum levels may take as long as 3 weeks to develop.

Lamotrigine (Lamictal)

 

Lamotrigine is a triazine derivative that is useful in the treatment of neuralgia. It inhibits the release of glutamate and inhibits voltage-sensitive sodium channels (thus stabilizing the neuronal membrane). For dose adjustments, follow the manufacturer's recommendations.

Topiramate (Topamax)

 

Topiramate's precise mechanism of action is unknown, but the following properties may contribute to its efficacy:

• Blockage of voltage-dependent sodium channels, as demonstrated by electrophysiologic and biochemical evidence

• Augmentation of GABA activity at some GABA-A receptor subtypes

• Antagonism of the AMPA/kainate subtype of the glutamate receptor

• Inhibition of carbonic anhydrase, particularly isozymes II and IV

Valproic acid (Depacon, Depakene, Stavzor)

 

The activity of valproic acid may be related to increased brain levels of GABA or enhanced GABA action.

Divalproex sodium (Depakote, Depakote ER)

 

The activity of divalproex sodium may be related to increased brain levels of GABA or enhanced GABA action.

Previous
Next

Anesthetics, Topical

Class Summary

Analgesics may aid in decreasing the severity of pain.

Lidocaine anesthetic (Topicaine, Lido Patch, Lidoderm 5% patch)

 

Several studies support topical administration of lidocaine as treatment of postherpetic neuralgia. In a placebo-controlled study, lidocaine gel (5%) yielded significant relief in 23 patients studied. Lidocaine tape also decreases the severity of pain.

Capsaicin topical (Dolorac, Capsin, Zostrix)

 

Capsaicin is a natural chemical derived from plants of the Solanaceae family. By depleting and preventing reaccumulation of substance P in peripheral sensory neurons, capsaicin may render treated areas insensitive to pain. Substance P is thought to be a chemomediator of pain transmission from the periphery to the CNS.

Previous
Next

Antiemetic Agents

Class Summary

Drugs of the cannabinoid class may aid in reducing neuropathic pain.

Dronabinol

 

Dronabinol is an orally active cannabinoid receptor agonist with complex effects on the CNS, including central sympathomimetic activity. Cannabinoid receptors have been discovered in neural tissues. These receptors play a role in mediating the effects of dronabinol and other cannabinoids. Dronabinol undergoes extensive first-pass hepatic metabolism by microsomal hydroxylation, yielding both active and inactive metabolites. It has also been shown to be highly plasma protein bound.

Several studies have shown dronabinol to have modest effects in treating neuropathic pain and muscle spasticity in individuals with demyelinating disease states.

Previous
 
Contributor Information and Disclosures
Author

Stanley J Krolczyk, DO, RPh Associate Professor, Director of Multiple Sclerosis Center, Department of Neurology, University of South Florida College of Medicine

Stanley J Krolczyk, DO, RPh is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Osteopathic Association, American Headache Society

Disclosure: Received grant/research funds from TEVA for clinical trials; Received consulting fee from TEVA for speaking and teaching; Received consulting fee from EMD SERONO for speaking and teaching; Received consulting fee from BIOGEN for speaking and teaching; Received grant/research funds from EMD SERONO for clinical trials; Received consulting fee from Novartis for speaking and teaching; Received grant/research funds from NOVARTIS for clinical trials.

Coauthor(s)

Martin A Myers, MD University of South Florida College of Medicine

Disclosure: Nothing to disclose.

Kavita Kalidas, MD Assistant Professor, Department of Neurology, University of South Florida College of Medicine

Kavita Kalidas, MD is a member of the following medical societies: American Academy of Neurology, American Medical Association, American Pain Society

Disclosure: Nothing to disclose.

Chief Editor

Robert A Egan, MD Director of Neuro-Ophthalmology and Stroke Service, St Helena Hospital

Robert A Egan, MD is a member of the following medical societies: American Academy of Neurology, American Heart Association, North American Neuro-Ophthalmology Society, Oregon Medical Association

Disclosure: Received honoraria from Biogen Idec for speaking and teaching; Received honoraria from Teva for speaking and teaching.

Acknowledgements

Joseph Carcione Jr, DO, MBA Consultant in Neurology and Medical Acupuncture, Medical Management and Organizational Consulting, Central Westchester Neuromuscular Care, PC; Medical Director, Oxford Health Plans

Joseph Carcione Jr, DO, MBA is a member of the following medical societies: American Academy of Neurology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

References
  1. Pascual J, Colas R, Castillo J. Epidemiology of chronic daily headache. Curr Pain Headache Rep. 2001 Dec. 5(6):529-36. [Medline].

  2. Zakrzewska JM. Multi-dimensionality of chronic pain of the oral cavity and face. J Headache Pain. 2013 Apr 25. 14(1):37. [Medline]. [Full Text].

  3. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004. 24 Suppl 1:9-160. [Medline].

  4. Kavuk I, Yavuz A, Cetindere U, Agelink MW, Diener HC. Epidemiology of chronic daily headache. Eur J Med Res. 2003 Jun 30. 8(6):236-40. [Medline].

  5. Mueller D, Obermann M, Yoon MS, Poitz F, Hansen N, Slomke MA, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011 Nov. 31(15):1542-8. [Medline].

  6. Bordini C, Antonaci F, Stovner LJ, Schrader H, Sjaastad O. "Hemicrania continua": a clinical review. Headache. 1991 Jan. 31(1):20-6. [Medline].

  7. Madland G, Feinmann C. Chronic facial pain: a multidisciplinary problem. J Neurol Neurosurg Psychiatry. 2001 Dec. 71(6):716-9. [Medline].

  8. Volcy M, Rapoport AM, Tepper SJ, Sheftell FD, Bigal ME. Persistent idiopathic facial pain responsive to topiramate. Cephalalgia. 2006 Apr. 26(4):489-91. [Medline].

  9. Kaup AO, Mathew NT, Levyman C, Kailasam J, Meadors LA, Villarreal SS. Side locked' migraine and trigeminal autonomic cephalgias: evidence for clinical overlap. Cephalalgia. 2003 Feb. 23(1):43-9. [Medline].

  10. Leone M, D'Amico D, Frediani F, Torri W, Sjaastad O, Bussone G. Clinical considerations on side-locked unilaterality in long-lasting primary headaches. Headache. 1993 Jul-Aug. 33(7):381-4. [Medline].

  11. Turp JC, Gobetti JP. Trigeminal neuralgia versus atypical facial pain. A review of the literature and case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Apr. 81(4):424-32. [Medline].

  12. Maarbjerg S, Sørensen MT, Gozalov A, Bendtsen L, Olesen J. Field-testing of the ICHD-3 beta diagnostic criteria for classical trigeminal neuralgia. Cephalalgia. 2014 Jul 22. [Medline].

  13. Cunningham AL, Dworkin RH. The management of post-herpetic neuralgia. BMJ. 2000 Sep 30. 321(7264):778-9. [Medline].

  14. Rozen TD. Trigeminal Autonomic Cephalgias. Continuum. 2006 Dec. 12:170-93.

  15. Watson P, Evans R. Cluster-tic syndrome. Headache. 1985 May. 25(3):123-6. [Medline].

  16. Pareja JA, Sjaastad O. SUNCT syndrome. A clinical review. Headache. 1997 Apr. 37(4):195-202. [Medline].

  17. Pareja JA, Ruiz J, de Isla C, al-Sabbah H, Espejo J. Idiopathic stabbing headache (jabs and jolts syndrome). Cephalalgia. 1996 Apr. 16(2):93-6. [Medline].

  18. Mokri B. Raeder's paratrigeminal syndrome. Original concept and subsequent deviations. Arch Neurol. 1982 Jul. 39(7):395-9. [Medline].

  19. Kuritzky A. Indomethacin-resistant hemicrania continua. Cephalalgia. 1992 Feb. 12(1):57-9. [Medline].

  20. Peres MF, Silberstein SD, Nahmias S, et al. Hemicrania continua is not that rare. Neurology. 2001 Sep 25. 57(6):948-51. [Medline].

  21. Cornelissen P, van Kleef M, Mekhail N, Day M, van Zundert J. Evidence-based interventional pain medicine according to clinical diagnoses. 3. Persistent idiopathic facial pain. Pain Pract. 2009 Nov-Dec. 9(6):443-8. [Medline].

  22. Jürgens TP, Müller P, Seedorf H, Regelsberger J, May A. Occipital nerve block is effective in craniofacial neuralgias but not in idiopathic persistent facial pain. J Headache Pain. 2012 Apr. 13(3):199-213. [Medline]. [Full Text].

  23. Vorenkamp KE. Interventional procedures for facial pain. Curr Pain Headache Rep. 2013 Jan. 17(1):308. [Medline].

  24. Yang HW, Huang YF. Treatment of persistent idiopathic facial pain (PIFP) with a low-level energy diode laser. Photomed Laser Surg. 2011 Oct. 29(10):707-10. [Medline].

  25. Ogutcen-Toller M, Uzun E, Incesu L. Clinical and magnetic resonance imaging evaluation of facial pain. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 May. 97(5):652-8. [Medline].

  26. Rozen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache. 2001 Nov-Dec. 41 Suppl 1:S25-32. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.